Cesca Therapeutics Inc. Announces Pricing of Public Offering of up to 900,000 shares of Common Stock
November 29 2017 - 9:07AM
Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in
automated cell processing and point-of-care, autologous cell-based
therapies, today announced that it has priced a best efforts
registered public offering of up to an aggregate of 900,000 shares
of the Company’s common stock at a price to the public of $3.00 per
share. The offering is expected to close on or about December 1,
2017, subject to the satisfaction of customary closing conditions.
Dawson James Securities, Inc. is acting as
exclusive placement agent for the offering.
The aggregate gross proceeds of the offering are
anticipated to be up to approximately $2.7 million. After deducting
the placement agent's commission and other estimated offering
expenses payable by the Company, the net proceeds to the Company
are anticipated to be up to approximately $2.3 million. Cesca
intends to use the net proceeds from this offering for general
corporate purposes, including working capital.
The shares are being offered pursuant to an
effective shelf registration statement on Form S-3, as amended
(File No. 333-212314), that was previously filed with the
Securities and Exchange Commission (SEC) and declared effective on
August 1, 2016. The securities may be offered only by means of a
prospectus. The prospectus has been filed with the SEC and is
available on the SEC's website located at http://www.sec.gov. The
preliminary prospectus supplement related to the offering will be
available on the SEC's website located at http://www.sec.gov and
may also be obtained from Dawson James Securities, Inc., Attention:
Prospectus Department, 1 North Federal Highway, 5th Floor, Boca
Raton, FL 33432, mmaclaren@dawsonjames.com, or toll free at
866.928.0928.
This press release shall not constitute an offer
to sell, or the solicitation of an offer to buy, nor may there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Cesca Therapeutics Inc.Cesca is a leading
regenerative medicine company that develops, commercializes and
markets a range of automated technologies for cell-based
therapeutics. Its device division, ThermoGenesis, provides a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. Cesca is also
leveraging its proprietary AutoXpress® technology platform to
develop an automated, functionally-closed CAR-TXpress platform that
addresses cellular manufacturing needs in the immuno-oncology
field.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Cesca’s current
expectations concerning future events and results. Forward-looking
statements based on Cesca’s current assumptions, expectations and
beliefs are generally identifiable by use of words “may,” “might,”
“will,” “should,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential” or “continue,” or similar
expressions and involve significant risks and uncertainties that
could cause actual results, developments and business decisions to
differ materially from those contemplated by these statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those risk factors discussed in Item 1A of our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission (“SEC”) as well as other documents that may be
filed by Cesca from time to time with the SEC, which are available
at www.sec.gov. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Company Contact: Cesca Therapeutics Inc. Wendy
Samford916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024